Century Therapeutics (IPSC) Accounts Payables (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Accounts Payables data on file, last reported at $3.2 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $3.2 million, down 11.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.2 million (down 11.84% YoY), and the FY2025 annual result was $4.8 million, up 55.22% from the prior year.
• Accounts Payables slipped to $3.2 million in Q1 2026 per IPSC's latest filing, from $4.8 million in the prior quarter.
• Over five years, Accounts Payables peaked at $9.9 million in Q1 2022 and troughed at $2.6 million in Q3 2024.
• A 5-year average of $4.2 million and a median of $3.5 million in 2023 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2022 and 2025: Accounts Payables tumbled 69.85% in 2022, then surged 55.22% in 2025.
• A 5-year view of Accounts Payables shows it stood at $5.5 million in 2022, then slumped by 49.74% to $2.7 million in 2023, then increased by 12.19% to $3.1 million in 2024, then surged by 55.22% to $4.8 million in 2025, then sank by 34.0% to $3.2 million in 2026.
• Business Quant data shows IPSC's Accounts Payables at $3.2 million in Q1 2026, $4.8 million in Q4 2025, and $2.6 million in Q3 2025.